Treatment of reactive arthritis with infliximab

Scandinavian Journal of Rheumatology

Volumn 32, Issue 2, 2003, Pages 122-124

  Kaipiainen Seppänen, Oili ^a   Niinisalo, Helena ^a   Korpilähde, Tuula ^a   Virolainen, Jukka ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ankylosing spondylitis; Infliximab; Reactive arthritis; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; ROXITHROMYCIN; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTHROPATHY; ARTICLE; CASE REPORT; CONVALESCENCE; DRUG EFFECT; DRUG RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; REACTIVE ARTHRITIS; TREATMENT OUTCOME; YERSINIA ENTEROCOLITICA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, REACTIVE; HUMANS; MALE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YERSINIA ENTEROCOLITICA;

EID: 0037257994     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740310000157     Document Type: Article

References (12)

1. Maini R, St Clair EW, Furst D, Kalden J, Weisman M, Smolen J, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
2. Lipsky PE, Van der Heijde DMFM, Clair EWST, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
3. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A Short.term study of chimeric monoclonal antibody cA2 to twnor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
4. Braun J, de Keyser F, Brandt J, Mielants H, Siepr J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.
5. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNF (monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
6. Keat A. Reiter's syndrome and reactive arthritis in perspective. N Engl J Med 1983;309:1606-15.
7. Leirisalo-Repo M, Suoranta H. Ten-year followup study of patients with Yersinia arthritis. Arthritis Rheum 1988;31:533-7.
8. Leirisalo-Repo M. Therapeutic aspects of spondyloarthropathies - a review. Scand J Rheumatol 1998;27:323-8.
9. Meador RJ, Hsia EC, Kitumnuaypong T, Schumacher HR. Is etanercept (Enbrel) effective in the treatment of reactive and undifferentiated arthritis? Arthritis Rheum 2001;44 Suppl: S348.
10. Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor α, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999;42:2039-44.
11. Hoogkamp-Korstanje JAA, Moesker H, Bruyn GAW. Ciprofloxacin v placebo for treatment of Yersinia enterocolitica triggered reactive arthritis. Ann Rheum Dis 2000;59:914-7.
12. Sieper J, Fendler C, Laitko S, Sörensen H, Gripenberg-Lerche C, Hiepe F, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum 1999;42:1386-96.